Squamous cell carcinoma – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:35:32 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Squamous cell carcinoma – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study Comparing Two Cisplatin Dosing Schedules with Radiation for Patients with Advanced Head and Neck Cancer https://clinicaltrials.eu/trial/study-comparing-two-cisplatin-dosing-schedules-with-radiation-for-patients-with-advanced-head-and-neck-cancer/ Wed, 29 Apr 2026 14:58:43 +0000 https://clinicaltrials.eu/trial/study-comparing-two-cisplatin-dosing-schedules-with-radiation-for-patients-with-advanced-head-and-neck-cancer/ This clinical trial is focused on studying treatments for advanced head and neck cancer, specifically a type called squamous cell carcinoma. The study is comparing two different schedules of a chemotherapy drug called cisplatin, which is used in combination with radiation therapy. Cisplatin is given as a solution through an infusion, which means it is delivered directly into the bloodstream through a vein. The trial will compare giving cisplatin every three weeks at a higher dose of 100 mg/m² to giving it weekly at a lower dose of 40 mg/m².

The purpose of the study is to determine if the weekly schedule of cisplatin is better in terms of reducing side effects, known as acute toxicity, compared to the three-week schedule. Additionally, the study aims to see if the weekly schedule is just as effective in terms of overall survival, which means how long patients live after starting treatment. The trial will also look at other outcomes, such as the cancer’s response to treatment and any long-term side effects.

Participants in the study will receive either the weekly or the three-week cisplatin treatment along with radiation therapy. The study will monitor patients over time to assess the effectiveness and safety of the treatments. This research is important for finding the best way to treat advanced head and neck cancer while minimizing side effects for patients.

]]> Study of ALX148 and Pembrolizumab for Patients with Advanced Head and Neck Cancer https://clinicaltrials.eu/trial/study-of-alx148-and-pembrolizumab-for-patients-with-advanced-head-and-neck-cancer/ Wed, 29 Apr 2026 14:29:49 +0000 https://clinicaltrials.eu/trial/study-of-alx148-and-pembrolizumab-for-patients-with-advanced-head-and-neck-cancer/ This clinical trial is focused on studying a type of cancer called advanced head and neck squamous cell carcinoma. This cancer can be challenging to treat, especially when it has spread to other parts of the body or cannot be removed by surgery. The study is testing a combination of two treatments: ALX148 and pembrolizumab. ALX148 is a new type of treatment that is given as an injection, while pembrolizumab, also known as Keytruda, is a well-known medication used to help the immune system fight cancer. Both treatments are administered through a vein, a method known as intravenous administration.

The purpose of this study is to see how well the combination of ALX148 and pembrolizumab works in improving the survival rate and response to treatment in patients with this type of cancer. Participants in the study will receive these treatments over a period of up to 24 months. The study will monitor how the cancer responds to the treatment and how long the effects last. It will also look at the safety of the treatment and any side effects that may occur.

Throughout the study, participants will have regular visits to the clinic for treatment and check-ups. These visits will include various tests to monitor the cancer and overall health. The study aims to provide valuable information on the effectiveness of combining ALX148 with pembrolizumab for treating advanced head and neck squamous cell carcinoma.

]]> Study of ALX148, Pembrolizumab, and Chemotherapy for Patients with Advanced Head and Neck Cancer https://clinicaltrials.eu/trial/study-of-alx148-pembrolizumab-and-chemotherapy-for-patients-with-advanced-head-and-neck-cancer/ Wed, 29 Apr 2026 14:29:20 +0000 https://clinicaltrials.eu/trial/study-of-alx148-pembrolizumab-and-chemotherapy-for-patients-with-advanced-head-and-neck-cancer/ This clinical trial is focused on studying a type of cancer called advanced head and neck squamous cell carcinoma. This cancer can be difficult to treat, especially when it has spread to other parts of the body or cannot be removed by surgery. The study is testing a combination of treatments to see how well they work together. The treatments being tested include a medication called ALX148, another medication known as pembrolizumab (also called Keytruda), and chemotherapy drugs. Chemotherapy is a type of cancer treatment that uses drugs to destroy cancer cells.

The purpose of the study is to evaluate how effective this combination of treatments is in improving the survival rate and response to treatment in patients who have not yet received treatment for their advanced cancer. Participants in the study will receive these treatments through an intravenous (IV) line, which means the medication is given directly into a vein. The study will last for up to 24 months, during which time the effects of the treatment will be closely monitored.

Throughout the study, researchers will assess various outcomes, such as how long patients live after starting the treatment and how well the cancer responds to the treatment. They will also monitor any side effects that may occur. This information will help determine if the combination of ALX148, pembrolizumab, and chemotherapy is a beneficial treatment option for patients with advanced head and neck squamous cell carcinoma.

]]> Study of Cemiplimab for Patients with Stage II to IV Cutaneous Squamous Cell Carcinoma https://clinicaltrials.eu/trial/study-of-cemiplimab-for-patients-with-stage-ii-to-iv-cutaneous-squamous-cell-carcinoma/ Wed, 29 Apr 2026 14:25:12 +0000 https://clinicaltrials.eu/trial/study-of-cemiplimab-for-patients-with-stage-ii-to-iv-cutaneous-squamous-cell-carcinoma/ This clinical trial is focused on studying a type of skin cancer known as cutaneous squamous cell carcinoma (CSCC), specifically in stages II to IV. The treatment being investigated is a medication called cemiplimab, which is also known by its code name REGN2810. Cemiplimab is administered as a solution for infusion, meaning it is given directly into the bloodstream through a vein. The purpose of the study is to evaluate how effective cemiplimab is when used before surgery to treat CSCC.

Participants in the study will receive cemiplimab before undergoing surgery. The study will monitor how well the cancer responds to the treatment by looking at the cancer cells under a microscope after surgery. This is known as a pathologic complete response. The study will also track other outcomes, such as how long participants live without the cancer coming back, any changes in the surgical plan, and any side effects experienced during the treatment.

The study aims to provide valuable information about the potential benefits of using cemiplimab as a pre-surgery treatment for CSCC. By understanding how the cancer responds to this treatment, researchers hope to improve future treatment options for patients with this type of skin cancer. Participants will be closely monitored throughout the study to ensure their safety and to gather important data on the effectiveness of cemiplimab.

]]> Study of Pembrolizumab as Additional Treatment for Patients with High-Risk Locally Advanced Cutaneous Squamous Cell Carcinoma After Surgery and Radiation https://clinicaltrials.eu/trial/study-of-pembrolizumab-as-additional-treatment-for-patients-with-high-risk-locally-advanced-cutaneous-squamous-cell-carcinoma-after-surgery-and-radiation/ Wed, 29 Apr 2026 14:24:57 +0000 https://clinicaltrials.eu/trial/study-of-pembrolizumab-as-additional-treatment-for-patients-with-high-risk-locally-advanced-cutaneous-squamous-cell-carcinoma-after-surgery-and-radiation/ This clinical trial is focused on studying a type of skin cancer called Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC). The study is investigating the use of a medication called Pembrolizumab, also known by its code name MK-3475, as an additional treatment after surgery and radiation therapy. Pembrolizumab is a solution given through an intravenous infusion, which means it is administered directly into the bloodstream through a vein. The trial will compare the effects of Pembrolizumab with a placebo, which is a substance with no active medication, to see if it helps prevent the cancer from coming back.

The purpose of the study is to evaluate how well Pembrolizumab works in keeping the cancer from returning after the initial treatments. Participants in the study will have already undergone surgery to remove the cancer and completed radiation therapy. They will then receive either Pembrolizumab or a placebo as part of the trial. The study will monitor participants over a period of time to assess their health and any changes in their condition.

Throughout the study, researchers will look at various outcomes, including how long participants remain free of cancer and their overall survival. They will also assess the quality of life of participants using a questionnaire designed to measure physical functioning and other aspects of well-being. The study aims to provide valuable information on the effectiveness of Pembrolizumab as an additional treatment for people with high-risk LA cSCC.

]]>